Setmelanotide (endocrine use)

Energy balance runs through the hypothalamic leptin-melanocortin pathway: leptin acts on POMC neurons, which release alpha-MSH, which activates MC4R on second-order neurons to suppress appetite. Any lesion upstream of MC4R, whether a genetic POMC, PCSK1 or LEPR deficiency, Bardet-Biedl syndrome, or physical destruction of the hypothalamus by a craniopharyngioma or its treatment, leaves MC4R itself intact but unstimulated, producing relentless hyperphagia. Setmelanotide bypasses the break by agonising MC4R directly. The 2026 approval for acquired hypothalamic obesity rests on the phase 3 TRANSCEND trial, where BMI fell 15.8 percent versus a 2.6 percent rise on placebo at 52 weeks. Notably it does not work for common polygenic obesity, where the pathway is not the limiting factor.

Targets: MC4R, Hypothalamic POMC pathway, Hyperphagia

• · Start 2.5 mg daily for 2 weeks, then increase to 3 mg if tolerated. Reduce to 2 mg if not.
• · Weight-banded and age-banded starting doses down to age 2 for genetic obesity and age 4 for acquired hypothalamic obesity, generally starting 1 to 2 mg and titrating over 2-week steps to a maximum of 3 mg.

Work out your exact syringe units →

• very commonSkin hyperpigmentation and new or darkening naevi— From MC1R cross-activation. Reversible on stopping, but requires a dermatological skin exam before and during treatment.
• very commonInjection-site reactions
• very commonNausea, vomiting and diarrhoea
• commonSpontaneous penile erections in males— A direct melanocortin effect. Patients should be warned, and priapism lasting over 4 hours needs urgent care.
• commonHeadache and abdominal pain
• uncommonDepression and suicidal ideation— Monitored for in trials; new or worsening mood symptoms warrant reassessment.

• Common polygenic obesity, where it does not work and should not be prescribed
• Pregnancy
• Known hypersensitivity
• Caution with pre-existing depression or suicidality
• Not for benign obesity in the absence of a confirmed genetic or hypothalamic cause

• cautionsemaglutide — Both suppress appetite by different mechanisms; combined use is not studied and gastrointestinal effects can compound.
• conflictmelanotan-2 — Both are melanocortin agonists; stacking multiplies pigmentation and priapism risk with no added benefit.

• · Full skin examination before starting and periodically during therapy
• · BMI or BMI Z-score at 12 to 16 weeks and then regularly
• · Mood and mental health screening
• · Growth in children

Prescription drug in the US and EU for its specific rare-disease indications only. It is not approved and not appropriate for general weight loss.

• Imcivree FDA prescribing information (label)
• TRANSCEND phase 3 trial of setmelanotide in acquired hypothalamic obesity, 2025-2026 (trial)
• Clement et al. 2020 Lancet Diabetes Endocrinology, setmelanotide in POMC and LEPR deficiency obesity (trial)

The leptin-melanocortin pathway is the central regulator of long-term energy balance, and it is a relay: adipose leptin acts on LepR on arcuate POMC neurons, POMC is cleaved by PCSK1 to alpha-MSH, and alpha-MSH activates MC4R on second-order paraventricular neurons to generate satiety. AgRP neurons provide the opposing inverse-agonist signal. Every one of the approved indications is a lesion somewhere upstream of MC4R with MC4R itself intact: POMC deficiency means no ligand, PCSK1 deficiency means the ligand is never processed, LEPR deficiency means the signal never reaches POMC, Bardet-Biedl syndrome disrupts ciliary trafficking of MC4R-pathway components, and acquired hypothalamic obesity from a craniopharyngioma or its surgery or radiotherapy physically destroys the neurons. Setmelanotide bypasses the break by agonising MC4R directly, and downstream Gs-cyclic AMP signalling in paraventricular neurons restores the satiety signal. Two things follow. First, it does nothing for common polygenic obesity, because in that setting the pathway is not the limiting factor, and the label is explicit about this. Second, the side effects are the predictable consequence of a melanocortin agonist that is selective but not exclusive: MC1R activation on melanocytes produces the near-universal skin hyperpigmentation and darkening of naevi, and MC4R activation in spinal and central pathways governing erectile function produces spontaneous erections, which is the same mechanism that made the related compound bremelanotide a treatment for sexual dysfunction. The hyperphagia response is the most striking clinical feature: patients and families frequently describe the relief of relentless food-seeking behaviour before any weight change is measurable, and in hypothalamic obesity that behavioural change is arguably the primary benefit.

The single biggest failure is prescribing it for the wrong obesity. It does not work in common polygenic obesity, the label says so, and prescribing it there wastes an enormous amount of money and sets the patient up for disappointment. Genetic confirmation or a documented hypothalamic lesion is the entry criterion, not a formality. Second, the skin: hyperpigmentation is near-universal and patients who were not warned find it distressing, and darkening naevi make melanoma surveillance harder, which is why the baseline dermatology examination is not optional. Third, spontaneous erections in males, including in adolescents, which is a conversation that has to happen before the first dose rather than after. Fourth, failing to apply the 12 to 16 week stopping rule and continuing an expensive drug in a non-responder indefinitely. Fifth, missing coexisting untreated hypopituitarism in hypothalamic obesity and attributing the resulting fatigue and weight to drug failure. Sixth, mood: these patients often carry psychiatric vulnerability from their underlying condition and any new depressive symptoms need attention rather than attribution.

1. 2.5 mgWeeks 1-2, adults — 2.5 mg subcutaneously once daily at the same time each day, rotating between abdomen, thigh and upper arm.
2. 3 mgWeek 3 onward, adults — Increase to 3 mg daily if tolerated. If not tolerated, drop back to 2 mg. Escalation is guided by tolerability, not by weight response, because the weight response takes months to declare itself.
3. 1 mgPaediatric starting dose — Weight-banded and age-banded starting doses, generally 1 to 2 mg, licensed down to age 2 for genetic obesity and age 4 for acquired hypothalamic obesity.
4. 2 mgPaediatric escalation, 2-week steps — Escalate in 0.5 to 1 mg steps every 2 weeks to a maximum of 3 mg.
5. 3 mgWeek 12-16 decision point — Assess BMI response at 12 to 16 weeks on the maintenance dose. Below about 5 percent BMI reduction, or no meaningful percentile shift in a child, the label directs stopping.

• MC4R in the hypothalamic paraventricular nucleus — Selective agonist; numeric affinity not resolved this session.

  Gs-cyclic AMP signalling restoring the satiety signal downstream of a broken leptin-melanocortin relay. Reduces hyperphagia within weeks and BMI over months.

• MC1R on melanocytes — Cross-activated at clinical doses

  Increased eumelanin synthesis, producing generalised skin hyperpigmentation and darkening or new appearance of naevi in the majority of patients. Reversible on stopping, but it mandates a dermatological skin examination before and during treatment.

• MC4R in spinal and central erectile pathways — Same receptor, different circuit

  Spontaneous penile erections in males, occasionally prolonged. Priapism beyond 4 hours needs urgent care.

• MC3R — Lower than MC4R

  Contribution to energy homeostasis is not well defined in humans.

• TRANSCEND (NCT05774756) Phase 3, randomised, double-blind, placebo-controlled · 52 weeks · 2026

  Change in BMI at 52 weeks in acquired hypothalamic obesity. Least-squares mean change in BMI was -16.5 percent with setmelanotide versus 3.3 percent with placebo, p less than 0.001.

• Clement 2020 phase 3 trials in POMC and LEPR deficiency obesity Phase 3, open-label, single-arm with a placebo-controlled withdrawal sequence · 2020

  Proportion of patients achieving at least 10 percent weight loss at approximately one year in severe obesity due to POMC or LEPR deficiency, alongside reductions in hunger scores. Both endpoints were met, which is what secured the 2020 approval.

Hunger scores frequently drop within the first two to four weeks, and families in hypothalamic obesity often describe that change as more meaningful than the weight itself. Weight and BMI change is formally assessed at 12 to 16 weeks, which is the label's decision point, and continues to accumulate over a year: the TRANSCEND BMI change was measured at 52 weeks. Skin hyperpigmentation appears within the first weeks and deepens over months, reversing after discontinuation. Injection-site reactions and nausea cluster early and settle. Steady state is reached within about three days given the 11 hour half-life, so there is no long loading period.

The obvious question is whether to combine with a GLP-1 receptor agonist or tirzepatide, and the honest answer is that it has not been studied and the gastrointestinal effects compound. Mechanistically the two are not redundant: incretins act on hindbrain and vagal satiety circuits and on gastric emptying, setmelanotide acts on the hypothalamic melanocortin relay, so there is a plausible additive case, and it is being explored in hypothalamic obesity where incretin monotherapy underperforms. Until there is data, treat combination as experimental. Do not stack with melanotan-2 or any other melanocortin agonist; the pigmentation and priapism effects multiply and there is no additional benefit. In hypothalamic obesity, the essential co-management is the rest of the pituitary: hydrocortisone, levothyroxine, sex steroids and desmopressin as required, all optimised before judging the drug. Behavioural and dietary support remains part of the package, though the point of the drug is that willpower was never the limiting factor in these patients.

Against GLP-1 receptor agonists and tirzepatide in hypothalamic obesity: incretins do produce some weight loss in this population but consistently underperform their results in common obesity, because the lesion sits in a circuit they do not address. Setmelanotide's TRANSCEND effect size, a 16.5 percent BMI reduction against a placebo group that gained, is large in a population that has historically been untreatable. Against bariatric surgery in hypothalamic obesity: surgery has been used and produces variable and often disappointing results for the same reason, and it is irreversible. Against setmelanotide's own genetic indications: the monogenic populations, POMC, PCSK1 and LEPR deficiency, are vanishingly rare, so acquired hypothalamic obesity is by far the largest population this drug will treat and the 2026 approval is the commercially significant one. Against doing nothing: hypothalamic obesity after craniopharyngioma treatment is relentless, socially devastating and previously had no effective therapy, which is the context in which the cost has to be judged.

Ultra-orphan pricing, widely reported in the region of hundreds of thousands of dollars per year in the US. I did not source a figure this session and will not invent one. Access is generally through a manufacturer support programme rather than at list price.

• ?Absolute bioavailability is not stated in the label.
• ?Blood-brain barrier penetration is marked partial. MC4R sits in the hypothalamus and the drug clearly reaches it, but the arcuate and paraventricular regions sit near circumventricular organs with a relatively permeable barrier, and the extent of general CNS access is not characterised.
• ?Neither trial's enrolment was confirmed against the papers, so participants is null in both. TRANSCEND is described elsewhere as enrolling around 140 patients.
• ?The Clement 2020 trials were single-arm with a withdrawal sequence rather than conventionally randomised, and the phase description reflects that.
• ?Long-term durability beyond one to two years, and whether the weight regain on discontinuation is complete, are not established.
• ?No cost figures were sourced.

• Setmelanotide for the Treatment of Acquired Hypothalamic Obesity Miller JL, et al., New England Journal of Medicine, 2026 · PMID 42418774

  The TRANSCEND trial behind the 2026 hypothalamic obesity approval. Note the published effect size, -16.5 percent versus 3.3 percent, which differs slightly from figures circulating in earlier press material.

• Efficacy and safety of setmelanotide, an MC4R agonist, in individuals with severe obesity due to LEPR or POMC deficiency: single-arm, open-label, multicentre, phase 3 trials Clement K, et al., Lancet Diabetes & Endocrinology, 2020 · PMID 33137293

  The original registration data for the monogenic indications.

• IMCIVREE (setmelanotide) injection - FDA prescribing information Rhythm Pharmaceuticals, DailyMed

  Source of the 8 hour median tmax, 75.2 L volume of distribution, 79.1 percent protein binding, 11 hour half-life, 7.15 L/h clearance, 39 percent unchanged urinary excretion and the full cyclic octapeptide chemical name.